Abstract
We recently identified CGA (coding for the alpha subunit of glycoprotein hormones) as a new estrogen receptor alpha (ERα)-responsive gene in human breast tumors. Here, we assessed the relationship between CGA status (as determined by real-time quantitative RT–PCR) and the response to tamoxifen therapy in a well-defined cohort of 125 ERα-positive postmenopausal breast cancer patients treated with primary surgery followed by adjuvant tamoxifen alone. CGA overexpression, observed in 37.6% of patients, was associated with good relapse-free survival (P=0.037; univariate analysis). CGA status, combined with ERBB2 status (a marker of poor outcome), was an independent predictor of the response to tamoxifen (P=0.020; multivariate analysis). CGA status, especially when combined with ERBB2 status, may thus provide useful predictive information on tamoxifen responsiveness in breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bièche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, Vidaud M . 1999 Clin. Chem. 45: 1148–1156
Bièche I, Parfait B, Le Doussal V, Olivi M, Rio M-C, Lidereau R, Vidaud M . 2001 Cancer Res. 61: 1652–1658
Borg A, Baldetorp B, Fernö M, Killander D, Olsson H, Rydén S, Sigurdsson H . 1994 Cancer lett. 81: 137–144
Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S . 1996 J. Clin. Oncol. 14: 2702–2708
Cox DR . 1972 J. R. Stat. Soc. (B) 34: 187–220
Diab SG, Elledge RM, Clark GM . 2000 J. Natl. Cancer Inst. 92: 550–556
Kaplan EL, Meier P . 1958 J. Am. Stat. Assoc. 53: 457–481
McGuire WL . 1980 Recent Prog. Horm. Res. 36: 135–156
Sjögren S, Inganäs M, Lindgren A, Holmberg L, Bergh J . 1998 J. Clin. Oncol. 16: 462–469
Têtu B, Brisson J . 1994 Cancer 73: 2359–2365
Acknowledgements
This work was supported by the Association pour la Recherche sur le Cancer and the Ministère de l'Enseignement Supérieur et de la Recherche. We thank the staff of Centre René Huguenin for their assistance in specimen collection and patient care.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bièche, I., Parfait, B., Noguès, C. et al. The CGA gene as new predictor of the response to endocrine therapy in ERα-positive postmenopausal breast cancer patients. Oncogene 20, 6955–6959 (2001). https://doi.org/10.1038/sj.onc.1204739
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204739
Keywords
This article is cited by
-
Identification of a 5-gene-risk score model for predicting luminal A-invasive lobular breast cancer survival
Genetica (2022)
-
Differential circular RNA expression profiles in umbilical cord blood exosomes from preeclampsia patients
BMC Pregnancy and Childbirth (2021)
-
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients
BMC Cancer (2011)
-
Capsaicin-induced inactivation of sensory neurons promotes a more aggressive gene expression phenotype in breast cancer cells
Breast Cancer Research and Treatment (2006)
